Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Other Non-Current Assets (2023 - 2025)

Monte Rosa Therapeutics' Other Non-Current Assets history spans 3 years, with the latest figure at $5.0 million for Q4 2025.

  • For Q4 2025, Other Non-Current Assets rose 1.87% year-over-year to $5.0 million; the TTM value through Dec 2025 reached $5.0 million, up 1.87%, while the annual FY2025 figure was $5.0 million, 1.87% up from the prior year.
  • Other Non-Current Assets reached $5.0 million in Q4 2025 per GLUE's latest filing, roughly flat from $5.0 million in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $5.3 million in Q1 2023 to a low of $440000.0 in Q1 2025.
  • Average Other Non-Current Assets over 3 years is $4.1 million, with a median of $4.9 million recorded in 2024.
  • Peak YoY movement for Other Non-Current Assets: grew 8.54% in 2024, then tumbled 90.95% in 2025.
  • A 3-year view of Other Non-Current Assets shows it stood at $4.6 million in 2023, then rose by 6.18% to $4.9 million in 2024, then increased by 1.87% to $5.0 million in 2025.
  • Per Business Quant, the three most recent readings for GLUE's Other Non-Current Assets are $5.0 million (Q4 2025), $5.0 million (Q3 2025), and $445000.0 (Q2 2025).